Glial tumor. Malignant neoplasm of brain, Brain, unspecified
Conditions
Interventions
Intervention 1: In atorvastatin (Intervention) group: Atorvastatin, tablet 40 mg, twice daily, one week before surgery and two weeks after the surgery. Intervention 2: In placebo (Control) group: Plac
Treatment - Drugs
Placebo
In atorvastatin (Intervention) group: Atorvastatin, tablet 40 mg, twice daily, one week before surgery and two weeks after the surgery.
In placebo (Control) group: Placebo of atorvastatin, tablet 40 mg, twice daily, one week before surgery and two weeks after the surgery.
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients undergone neurosurgery with suggested diagnosis of glial tumor. Exclusion criteria: Atorvastatin contraindications: atorvatatin sensitivity, active hepatic disease, pregnancy and lactation. elevated liver enzymes; serious adverse reaction induced by atorvastatin; severe renal or hepatic failure; having infectious disease; use of atorvastatin before the study; pathology report of other type of tumors instead of glioma; serious interaction between patients medication with atorvastatin; MAP< 70 mmHg; Na<130mEq/L; Hematocrit<28%.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MMP-9. Timepoint: At the beginning of study, before surgery, 24 hour and two weeks after the surgery. Method of measurement: Lab test.;Karnofsky Performance Scale. Timepoint: Before and 2 months after the surgery. Method of measurement: Karnofsky Performance Scale criteria. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Kheirollah Gholami
Tehran University of Medical Sciences
Outcome results
None listed